🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Taiyuan
Clinical trial register · China

Clinical Trials in Taiyuan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Shanxi Bethune Hospital15 Cancer Institute and Hospital, Chinese Academy of Medical Sciences6 Second Hospital of Shanxi Medical University6 Alexion Pharmaceuticals, Inc.4 Shanxi Province Cancer Hospital4
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Taiyuan

144 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors
NCT06500091Soft Tissue Sarcoma, Melanoma
DrugsTQB2916·Doxorubicin Hydrochloride·Penpulimab
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
54
Beijing, Zhengzhou, Changsha, Changchun, Jinan, Shanghai, Taiyuan, Tianjin
2024-07
Active, closed
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
NCT05562947Neovascular Age-related Macular Degeneration, nAMD
DrugRanibizumab
Hoffmann-La Roche
Phase 3
68
Beijing, Chengdu, Guangzhou, Harbin, Qingdao, Shanghai, Shenyang, Taiyuan
2024-06-17
Recruiting
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
NCT06508983Relapsed/Refractory Multiple Myeloma
DrugsSG301·Pomalidomide·Dexamethasone
Hangzhou Sumgen Biotech Co., Ltd.
Phase 3
360
Beijing, Guangzhou, Luoyang, Zhengzhou, Wuhan, Suzhou, Taiyuan, Xi’an
2024-06-14
Recruiting
Umbilical Cord Blood-Supported Haplo-HSCT for Aplastic Anemia Treatment Study
NCT06650553Aplastic Anemias
Shanxi Bethune Hospital
Not applicable
110
Taiyuan
2024-06-01
Recruiting
An Open-label, Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetic/Pharmacodynamic (PK/PD) Characteristics of SR604 Injection in Patients With Hemophilia A/B and Congenital Factor VII Deficiency
NCT07644832Hemophilia A, Hemophilia B, Factor VII Deficiency
DrugSR604
Shanghai RAAS Blood Products Co., Ltd.
Phase 1/2
76
Changsha, Hefei, Jinan, Lanzhou, Shanghai, Taiyuan, Tianjin, Xi'an
2024-05-31
Recruiting
Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen
NCT06251947Ovarian Cancer, Cervical Cancer
DrugEfbemalenograstim alfa
Shandong University
Phase 2
83
Changsha, Nanjing, Jinan, Qingdao, Taiyuan, Hangzhou
2024-04-15
Recruiting
Efficacy of Songling Xuemaikang Capsules on Grade 1 Hypertension: a Randomized Controlled Trial
NCT06093932Hypertension,Essential
DrugSongling Xuemaikang
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase 4
100
Beijing, Suzhou, Jinan, Jining, Taiyuan
2024-04-07
Recruiting
Disitamab Vedotin Plus Intravesical Mitomycin C in HER2-Expressing Intermediate- to High-Risk Non-Muscle-Invasive Bladder Cancer
NCT07646145Non-Muscle-Invasive Bladder Cancer (NMIBC)
DrugsMitomycin C·Disitamab Vedotin
Shanxi Province Cancer Hospital
Phase 2
30
Taiyuan
2024-04-01
Recruiting
A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children
NCT06305663Myopia
Bausch & Lomb Incorporated
Not applicable
418
Beijing, Dongcheng, Xiamen, Haikou, Wuhan, Shanghai, Taiyuan, Shenzhen
2024-03-29
Not yet open
A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients
NCT06255704Mantle Cell Lymphoma
Shanxi Province Cancer Hospital
Phase 2
23
Taiyuan
2024-03-15
Not yet open
JY231(Internal Clinical Drug Code) Injection for the Treatment of Refractory Autoimmune Diseases
NCT06243159Autoimmune Diseases
Shanxi Bethune Hospital
Phase EARLY_PHASE1
20
Taiyuan
2024-02-08
Active, closed
Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
NCT06196840Neovascular Age-Related Macular Degeneration
DrugAflibercept
Innostellar Biotherapeutics Co.,Ltd
Phase 2
50
Hefei, Hangzhou, Beijing, Chengdu, Guangzhou, Shanghai, Taiyuan, Tianjin
2024-01-24
Recruiting
A Novel CAR-T Combined Expression of IL-15 in the Treatment of Malignant Hematological Tumors
NCT06783816Acute Lymphocytic Leukemia, Lymphoma,Non-Hodgkin, Relapsed Refractory Multiple Myeloma
Shanxi Bethune Hospital
Not applicable
45
Taiyuan
2023-12-01
Not yet open
Predictive Value of HBV pgRNA on Long-term Outcomes in Hepatitis B Patients Treated With Antiviral Therapy
NCT05965388HBV, HCC
DrugInterferon
Wen-hong Zhang
Observational
5,000
Hefei, Fuzhou, Wuhan, Nanjing, Xuzhou, Jinan, Taiyuan, Xi’an
2023-12-01
Active, closed
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years
NCT06041061HPV InfectioN, HPV-Related Carcinoma
Sinocelltech Ltd.
Phase 3
18,000
Nanning, Zhengzhou, Taiyuan, Chengdu, Kunming
2023-08-13
Recruiting
A Phase 1/2 Study of CG001419 Tablets in Adult Subjects With Locally Advanced or Metastatic Solid Tumours Harbouring NTRK Gene Abnormalities
NCT07394374Solid Tumors Harboring NTRK Fusion, NTRK, NTRK Gene Fusion, NTRK Fusion Positive
Cullgen (Shanghai),Inc
Phase 1/2
42
Beijing, Chengdu, Guangzhou, Hangzhou, Taiyuan
2023-06-20
Recruiting
A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer
NCT05913089Non Small Cell Lung Cancer
DrugsAnlotinib hydrochloride·Etoposide
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
58
Beijing, Fuzhou, Weifang, Shanghai, Taiyuan, Tianjin
2023-06-14
Recruiting
SG1906 for CLDN18.2-Positive Solid Tumors
NCT05857332Locally Advanced Unresectable or Metastatic Solid Tumors
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1
60
Beijing, Xiamen, Guangzhou, Zhengzhou, Shenyang, Taiyuan, Hangzhou
2023-05-30
Active, closed
SeQuent ® Please CIS for the Treatment of INtracranial Atherosclerotic Stenosis
NCT06047964Stroke, Intracranial Atherosclerotic Stenosis
B. Braun Medical International Trading Company Ltd.
Not applicable
281
Beijing, Harbin, Nanyang, Changchun, Jining, Qingdao, Shanghai, Taiyuan
2023-03-23
Recruiting
Tislelizumab in Combination With Pre-operative CRT Versus SOC for Locally Advanced G/GEJ Adenocarcinoma
NCT05687357Gastric Cancer, Gastroesophageal-junction Cancer
DrugsTegafur Gimeracil Oteracil·Nab-paclitaxel·Oxaliplatin·Tislelizumab
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
140
Wuhan, Nanjing, Taiyuan
2023-03-15
Recruiting
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
NCT05726110Relapsed or Refractory Acute Myeloid Leukemia
DrugsAclacinomycin·Granulocyte Colony-Stimulating Factor·Homoharringtonine·Daunorubicin
Shanxi Bethune Hospital
Phase 3
50
Taiyuan
2023-01-29
Active, closed
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
NCT05662241IgG4 Related Disease
DrugObexelimab
Zenas BioPharma (USA), LLC
Phase 3
194
Beijing, Shijiazhuang, Wuhai, Yantai, Shanghai, Taiyuan, Chengdu
2023-01-09
Recruiting
Prediction of Peritoneal Metastasis for Gastric Cancer Based on Radiomics
NCT05722275Gastric Cancer, Peritoneal Metastases
Chinese Academy of Sciences
Observational
400
Beijing, Fuzhou, Guangzhou, Guiyang, Kunming, Taiyuan, Zhengzhou, Zhenjiang
2023-01-01
Recruiting
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
NCT05618041Acute Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma
Hebei Senlang Biotechnology Inc., Ltd.
Not applicable
50
Taiyuan
2022-09-07
Active, closed
Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome
NCT05349214Sjogren Syndrome
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
506
Hefei, Chongqing, Nanjing, Nanchang, Pingxiang, Changchun, Taiyuan, Chengdu
2022-08-04
Active, closed
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997Multiple Myeloma
DrugsIberdomide·Bortezomib·Daratumumab·Dexamethasone
Celgene
Phase 3
939
Changsha, Nanchang, Xi'an, Shanghai, Taiyuan, Wenzhou, Beijing, Changchun
2022-06-23
Active, closed
Application of Polygenic Methylation Markers in Postoperative Recurrence Monitoring of Colorectal Cancer
NCT05444491Colorectal Cancer
Singlera Genomics Inc.
Observational
800
Beijing, Chengdu, Guangzhou, Haerbin, Shanghai, Shenzhen, Taiyuan
2022-06-20
Recruiting
Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)
NCT05145361NMO Spectrum Disorder
DrugB001
Shanghai Pharmaceuticals Holding Co., Ltd
Phase EARLY_PHASE1
45
Beijing, Taiyuan, Xi’an, Tianjin
2022-04-07
Active, closed
A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease
NCT05206773Fabry Disease
DrugVenglustat
Sanofi
Phase 3
122
Beijing, Shanghai, Taiyuan, Zhengzhou
2022-03-11
Active, closed
Evaluation of the Safety and Efficacy of Hemophilia B Gene Therapy Drug
NCT05203679Hemophilia B
Shanghai Xinzhi BioMed Co., Ltd.
Phase 2/3
32
Hefei, Beijing, Guangzhou, Shenzhen, Tangshan, Zhengzhou, Taiyuan, Tianjin
2021-12-30
Active, closed
SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.
NCT05022654Esophageal Squamous Cell Carcinomas
DrugsSI-B001·Irinotecan
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
22
Beijing, Anyang, Luoyang, Xuzhou, Taiyuan, Suining
2021-12-13
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
NCT05156281Relapsing Multiple Sclerosis
DrugsTeriflunomide·Remibrutinib
Novartis Pharmaceuticals
Phase 3
1,007
Wuhan, Nanjing, Yinchuan, Taiyuan, Hangzhou, Wenzhou, Beijing, Shanghai
2021-12-13
Recruiting
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
NCT05194982Locally Advanced or Metastatic Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
570
Chongqing, Guangzhou, Wuhan, Changsha, Shanghai, Taiyuan
2021-11-29
Active, closed
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462Primary IgA Nephropathy
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
448
Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Changchun, Yinchuan, Taiyuan
2021-09-20
Active, closed
Multi-centre Study to Evaluate ACAF Versus Laminoplasty in Treating Cervical Ossification of the Posterior Longitudinal Ligament
NCT04968028Ossification of Posterior Longitudinal Ligament, Cervical Spondylosis With Myelopathy
Shanghai Changzheng Hospital
Not applicable
167
Beijing, Shenzhen, Harbin, Jining, Qingdao, Shanghai, Taiyuan, Xi’an
2021-08-17
Recruiting
Cardioprotective Effect of Dexmedetomidine in Patients With ST-segment Elevation Myocardial Infarction
NCT04912518ST-segment Elevation Myocardial Infarction (STEMI), Percutaneous Coronary Intervention, Cardioprotection
DrugMidazolam
Harbin Medical University
Not applicable
250
Hefei, Lanzhou, Harbin, Mudanjiang, Zhengzhou, Wuhan, Xi'an, Taiyuan
2021-05-27
Active, closed
An Observational Study to Evaluate the Real-World Clinical Management and Outcomes of ALK-Positive Advanced NSCLC Participants Treated With Alectinib
NCT04764188NSCLC
DrugAlectinib
Hoffmann-La Roche
Observational
800
Changsha, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing, Nanning, Taiyuan
2021-05-10
Recruiting
Drug-Eluting Registry: Real-World Treatment of Lesions in the Peripheral Vasculature
NCT04674969Peripheral Vascular Diseases
Boston Scientific Corporation
Observational
5,000
Chaoyang, Xicheng, Chongqing, Guangzhou, Qingdao, Huangpu, Yangpu, Taiyuan
2021-03-29
Active, closed
An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
NCT04717414Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis
DrugACE-536
Celgene
Phase 3
313
Guangzhou, Nanyang, Changsha, Nanjing, Nantong, Nanchang, Qingdao, Taiyuan
2021-02-25
Active, closed
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
NCT04233346Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia
Otsuka Beijing Research Institute
Phase 2
93
Hefei, Guangzhou, Wuhan, Changsha, Suzhou, Shenyang, Jinan, Taiyuan
2020-07-09
By invitation
Comparative Study Between UBE and PETD for the Treatment of Lumbar Spinal Canal Stenosis
NCT05033457Lumbar Disc Herniation
Shaanxi Provincial People's Hospital
Observational
100
Taiyuan
2018-01-01
Active, closed
Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer
NCT03036098Urothelial Cancer
DrugsIpilimumab·Nivolumab·Gemcitabine·Cisplatin
Bristol-Myers Squibb
Phase 3
1,314
Beijing, Chongqing, Guiyang, Harbin, Wuhan, Nanjing, Changchun, Taiyuan
2017-03-24
Active, closed
Dexmedetomidine Supplemented Analgesia and Long-term Survival After Cancer Surgery
NCT03012971Elderly, Surgery, Analgesia, Dexmedetomidine
Peking University First Hospital
Not applicable
1,500
Beijing, Chongqing, Guiyang, Baoding, Changsha, Xi'an, Qingdao, Taiyuan
2017-01-06
Active, closed
Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature
NCT02375620Short Stature Children Born Small for Gestational Age (SGA)
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 2
96
Beijing, Wuhan, Changsha, Wuxi, Nanchang, Changchun, Shanghai, Taiyuan
2015-04-23
Rows per page Showing 101–144 of 144
Previous 1 2
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/taiyuan?page=2

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 144 of those studies with a site in Taiyuan.

How many clinical trials are recruiting in Taiyuan?

93 of the 144 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 22 have not yet opened recruitment, 28 are active but closed to new participants, and 1 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.